EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 3.0

Oral anticoagulants and hepatic decompensation in patients with cirrhosis and atrial fibrillation: observational study

Axel Wester, Emilie Toresson Grip, Rupesh Rajani, Anthony A Matthews, Hannes Hagström, Ying Shang

Clinical and Molecular Hepatology · 01.10.2026 · 32 (4) · e2026.0286

DOI: 10.3350/cmh.2026.0286 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2026. Verfasst von Axel Wester und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. axel.wester@ki.se. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Mag-tarmfonden, Bengt Ihre foundation, Professor Nanna Svartz foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Oral anticoagulants may reduce risk of hepatic decompensation in patients with compensated cirrhosis, but well-powered randomized trials are missing. We aimed to estimate the effect of oral anticoagulants on risk of hepatic decompensation and major bleeding in patients with compensated cirrhosis and atrial fibrillation.

Methods

Observational data from Swedish healthcare registers 2011–2022 were used to emulate a target trial of oral anticoagulants in patients with compensated cirrhosis and newly diagnosed atrial fibrillation. Inverse-probability weighted marginal structural models were used to compare 5-year risks of hepatic decompensation and non-portal hypertension-related major bleeding in initiators vs. non-initiators of oral anticoagulants.

Results

The study included 1,160 patients (715 males [61.6%]; median [p25–p75] age of 73 years [67–79]). The adjusted 5-year risk of hepatic decompensation was 10.4% (33/383) in initiators and 16.6% (112/777) in non-initiators (risk ratio [RR]=0.62, 95% confidence interval [CI]=0.33–0.92), corresponding to a number needed to treat of 17 (95% CI=9–112). The risk reduction was primarily driven by a reduced risk of ascites (RR=0.58, 95% CI=0.26–0.90). The risk of major bleeding was 19.0% (63/383) in initiators and 19.8% (149/777) in non-initiators (RR=0.96, 95% CI=0.64–1.28). Risks were similar between treatment groups regarding fatal, intracranial, gastrointestinal, and other bleedings.

Conclusions

In this nationwide observational study, patients with compensated cirrhosis and atrial fibrillation who initiated oral anticoagulants had lower risk of hepatic decompensation, and similar risk of major bleeding compared to non-initiators. The results suggest oral anticoagulants are safe in patients with compensated cirrhosis and may improve prognosis. Randomized trials are warranted to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsAtrial FibrillationLiver CirrhosisAgedFemaleHumansMaleAdministration, OralAscitesHemorrhageRegistriesRisk FactorsSweden

Stichwörter der Autor:innen

AnticoagulationEmulated target trialLiver diseasesMarginal structural model

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. axel.wester@ki.se.
  • Clinical Pharmacology, Karolinska University Hospital, Huddinge, Stockholm, Sweden. axel.wester@ki.se.
  • Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Quantify Research, Stockholm, Sweden.
  • Division of Hepatology, Department of Upper Gastroenterology, Karolinska University Hospital, Stockholm, Sweden.
  • Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Förderung

  • Mag-tarmfonden
  • Bengt Ihre foundation
  • Professor Nanna Svartz foundation
  • Stockholm County Council
  • Gastroenterologisk forskningsfond
  • Swedish Society of Medicine
  • Ruth and Richard Julin foundation
  • Research Program in Epidemiology at Karolinska Institutet, Forte

Zitieren

APA

Wester, A., Grip, E. T., Rajani, R., Matthews, A. A., Hagström, H., & Shang, Y. (2026). Oral anticoagulants and hepatic decompensation in patients with cirrhosis and atrial fibrillation: observational study. Clinical and Molecular Hepatology, 32(4), e2026.0286. https://doi.org/10.3350/cmh.2026.0286

Vancouver

Wester A, Grip ET, Rajani R, Matthews AA, Hagström H, Shang Y. Oral anticoagulants and hepatic decompensation in patients with cirrhosis and atrial fibrillation: observational study. Clinical and Molecular Hepatology. 2026;32(4):e2026.0286. doi:10.3350/cmh.2026.0286

BibTeX
@article{Wester2026,
  author = {Wester, Axel and Grip, Emilie Toresson and Rajani, Rupesh and Matthews, Anthony A and Hagström, Hannes and Shang, Ying},
  title = {Oral anticoagulants and hepatic decompensation in patients with cirrhosis and atrial fibrillation: observational study},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {4},
  pages = {e2026.0286},
  doi = {10.3350/cmh.2026.0286}
}
Kostenlos starten →